Actively Recruiting
Evolution and Treatments of Chronic Inflammatory Systemic Diseases
Led by Centre Hospitalier Universitaire de Besancon · Updated on 2024-11-27
3000
Participants Needed
1
Research Sites
520 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Patients with chronic inflammatory diseases (CID) followed in gastroenterology, dermatology and rheumatology have physiopathological, epidemiological and therapeutic focal points. The pathologies concerned are inflammatory bowel diseases (IBD - Crohn's disease \[MC\] and ulcerative colitis \[RCH\]), chronic inflammatory skin diseases (psoriasis or Verneuil's disease) and chronic inflammatory rheumatic diseases (rheumatoid arthritis \[RA\] and spondyloarthritis \[SpA\] including psoriatic arthritis \[PsA\]). Presenting one of these diseases is associated with a higher risk of having a second inflammatory pathology, whether the latter is ophthalmological, dermatological, rheumatological or gastroenterological. An association of extra-articular manifestations is observed in 10 to 30% of patients with SpA, and an association of extra-intestinal manifestations is observed in approximately 30% of patients with IBD. No common database for chronic systemic inflammatory diseases currently exists in France.
CONDITIONS
Official Title
Evolution and Treatments of Chronic Inflammatory Systemic Diseases
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients treated for inflammatory bowel diseases (Crohn's disease, ulcerative colitis, or indeterminate colitis) in the gastroenterology department of Besançon University Hospital
- Patients meeting the clinical, morphological, and histological diagnostic criteria for Crohn's disease, ulcerative colitis, or indeterminate colitis
- Patients treated for chronic inflammatory rheumatism (rheumatoid arthritis, spondyloarthritis, psoriatic arthritis) in the rheumatology department of Besançon University Hospital
- Patients meeting the ACR 2010 classification criteria for rheumatoid arthritis, modified New York criteria for ankylosing spondylitis, ASAS criteria for axial or peripheral spondyloarthritis, or CASPAR criteria for psoriatic arthritis
- Patients treated for chronic inflammatory skin diseases (psoriasis or Verneuil's disease) in the dermatology department of Besançon University Hospital
You will not qualify if you...
- Patient refusal to participate
- Patients in emergency situations
- Persons deprived of their liberty
- Protected minors or adults
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CHU Besançon
Besançon, France, 25000
Actively Recruiting
Research Team
C
Charline Vauchy, PhD
CONTACT
S
Stéphanie François
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here